Acadia has announced the acquisition of a private US biotech, CerSci Therapeutics.
Acadia paid US$52.5 million upfront in a cash-and-stock deal— US$47.2 million of it in Acadia shares. CerSci shareholders will also be eligible for up to US$887 million more in payments, plus royalties, dependent on development, commercialization, and sales milestones being met.
CerSci’s lead, early-stage asset is ACP-044, a potential therapy for both acute post-surgical and chronic nerve pain, which is designed to interfere with multiple pain pathways without presenting an addiction risk. A Phase 1 trial is planned for H1 2021.
CerSci also has preclinical programs in migraine and painful diabetic neuropathy and discovery-stage programs in neurodegenerative disease and opioid use disorder.
https://ir.acadia-pharm.com/sec-filings
https://www.fiercebiotech.com/biotech/acadia-adds-pain-meds-to-pipeline-52-5m-cersci-buyout
https://xconomy.com/san-diego/2020/...s-cersci-potential-pain-meds-in-52-5m-buyout/
https://cersci.com/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.78 |
Change
0.230(1.31%) |
Mkt cap ! $2.240B | |||
| Open | High | Low | Value | Volume |
| $17.83 | $17.99 | $17.35 | $16.12M | 911.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11000 | $17.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.80 | 10070 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |